** Drug developer Pliant Therapeutics' shares PLRX.O fall 55.9% to $3.43 premarket
** Late Friday, co said it voluntarily paused enrollment and dosing in mid-stage trial testing its experimental lead drug, bexotegrast, to treat a type of lung disease called idiopathic pulmonary fibrosis
** Idiopathic pulmonary fibrosis is a chronic lung disease that causes scarring and stiffening of the organ's tissue
** At least 3 brokerages downgrade stock
** "This could turn out to be nothing, or it could spell the end for bexotegrast" - brokerage H.C. Wainwright
** Brokerage RBC Capital Markets also cuts to "sector perform" from "outperform", and slashes PT to $4 from $45
** Best-case scenario for co would be resuming study, but this may require some modification of the trial, which may lead to disruption and add risks - RBC
** Stock was down 26% in 2024
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.